Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

Venook, Alan P.; Niedzwiecki, Donna; Innocenti, Federico; Fruth, Briant; Greene, Claire; O’Neil, Bert H.; Shaw, James E.; Atkins, James N.; Horvath, Laura E.; Polite, Blasé N.; Meyerhardt, Jeffrey A.; O'Reilly, Eileen Mary; Goldberg, Richard M.; Hochster, Howard S.; Blanke, Charles D.; Schilsky, Richard L.; Mayer, Robert J.; Bertagnolli, Monica M.; Lenz, Heinz‐Josef

doi:10.1200/jco.2016.34.15_suppl.3504

Cited by 333 publications

(337 citation statements)

References 0 publications

Supporting

Mentioning

299

Contrasting

Unclassified

Order By: Relevance

“…в группе с бевацизумабом. Не отмечено зависимости меж-ду чувствительностью опухоли к тому или иному режиму химиотерапии (FOLFOX или FOLFIRI) и локализацией пер-вичной опухоли [29]. Несмотря на такую разницу в пока-зателях выживаемости, необходимо учитывать, что это результаты ретроспективного анализа и группы сравнения могут быть не сбалансированы по прогностическим фак-торам.…”

Section: какой таргетный препарат выбрать в первой линии леченияunclassified

Optimal Sequences and Combination of Chemotherapy and Monoclonal Antibodies in the Treatment of Patients With Metastatic Colorectal Cancer

Федянин¹,

Тюляндин²

2018

Zlokač. opuholi

View full text Add to dashboard Cite

In this review we analyzed results of studies concerning the choice of first and subsequent lines of therapy in patients with metastatic colon cancer. We discussed data of various combinations of monoclonal antibodies with different chemotherapeutic regimens. Also we discussed modern preclinical and clinical trials concerning strategy of choice of targeted therapy sequence in patients with metastatic disease. We considered the impact of various molecular and clinical factors on the effectiveness of drugs and determined their application for therapy choice for colon cancer.

show abstract

Section: какой таргетный препарат выбрать в первой линии леченияunclassified

Optimal Sequences and Combination of Chemotherapy and Monoclonal Antibodies in the Treatment of Patients With Metastatic Colorectal Cancer

Федянин¹,

Тюляндин²

2018

Zlokač. opuholi

View full text Add to dashboard Cite

show abstract

“…A retrospective analysis of ptl in that trial was first presented at the 2016 American Society of Clinical Oncology annual meeting 36 and updated in a recently published meta-analysis 28 . Those analyses showed that, in patients with lcc, treatment with cetuximab was associated with a median os duration of 39.3 months; treatment with bevacizumab was associated with a median os duration of 32.6 months (hr: 0.77; p = 0.04).…”

Section: Impact Of Ptl On Therapy With Either Egfr Mabs or Bevacizumabmentioning

confidence: 99%

The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement

et al. 2017

View full text Add to dashboard Cite

In recently published data, the predictive value of primary tumour location for the treatment of metastatic colorectal cancer with available biologic therapies has been explored. Recognizing the potential effect of those data on clinical practice, we convened a meeting of Canadian experts who treat metastatic colorectal cancer to develop a set of national, evidence-based treatment guidelines based on primary tumour location. This report summarizes the relevant evidence and presents the consensus recommendations of those experts.

show abstract

“…Recently a planned post-hoc analysis of the CALGB 80405 study demonstrated that right-sided colon cancers are also significantly less responsive to anti-EGFR therapies in the first-line setting (40).…”

Section: Anatomy As a Surrogate For Biology: Right-vs Left-sided Colmentioning

confidence: 99%

“…Like treatment with cetuximab or panitumumab in KRAS WT patients, the responses are initially evident but eventually resistance develops, with an improvement in PFS of around 2 months (62). Mutations in KRAS, NRAS, BRAF or PIK3CA have not been shown to alter sensitivity to bevacizumab therapy (40,63) Clinical benefit in gastric cancer with bevacizumab is mixed. In the AVAGAST study, improvements in PFS and RR were evident in patients with gastric cancer, but the primary endpoint of OS was not met (64).…”

Section: Resistance To Vegf Inhibitors: Primary and Acquiredmentioning

confidence: 99%

Primary and acquired resistance to biologic therapies in gastrointestinal cancers

Lubner

Uboha

Deming

2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Improvements in the understanding of cancer biology have led to therapeutic advances in the treatment of gastrointestinal cancers. Drugs which target the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways have led the way in colon cancer. Monoclonal antibodies (mAbs) such as bevacizumab, ramucirumab, cetuximab, and panitumumab, have improved progression free survival and overall survival (OS) for colorectal cancers and were quickly adopted. Human epidermal growth factor receptor 2 (HER2) has demonstrated significant benefit for gastroesophageal cancers and in the setting of HER2 amplification, trastuzumab in combination with chemotherapy has become the standard of care. However, responses have not been as durable nor as robust as once hoped. Mechanisms of resistance for each of these biologic compounds have been hypothesized and are in the process of being better elucidated. This review will approach the innate and acquired mechanisms of resistance of the above compounds.Additionally, we will explore some ongoing clinical trials to capitalize on the mechanisms of resistance in the hopes of retaining the promise of targeting these pathways. Resistance to EGFR inhibitors: primaryAs many tumors of the gastrointestinal tract arise from epithelial origins, the attractiveness of treating with therapies blocking EGFR is readily evident. A series of colon cancer trials have shown, improvements in RRs and OS, particularly in populations without mutations in EGFR and/or downstream effectors, which are described in the next section. In most other GI cancers, however, blocking EGFR has not demonstrated clinically relevant improvements in outcome (2-4). New strategies to investigate anti-EGFR therapy in other tumor types are focusing on selecting for patients whose tumors overexpress EGFR, or do not harbor deleterious mutations (ENRICH study, NCT 01813253) (5). KRAS/NRASKRAS and NRAS belong to the family of RAS oncogenes.

show abstract

Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

Cited by 333 publications

References 0 publications

Optimal Sequences and Combination of Chemotherapy and Monoclonal Antibodies in the Treatment of Patients With Metastatic Colorectal Cancer

Optimal Sequences and Combination of Chemotherapy and Monoclonal Antibodies in the Treatment of Patients With Metastatic Colorectal Cancer

The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement

Primary and acquired resistance to biologic therapies in gastrointestinal cancers

Contact Info

Product

Resources

About